Actively Recruiting
tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder
Led by Centre Hospitalier Henri Laborit · Updated on 2025-06-05
25
Participants Needed
1
Research Sites
193 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-center study about patients with severe resistant OCD. Main assumption is that performing 10 tDCS sessions with the anode positioned at the level of the right orbitofrontal cortex, and the cathode at the level of the supplementary motor area, associated with the provocation of symptoms before each session is effective in the reduction in obsessive-compulsive symptoms. After the inclusion visit, the treatment period is provided from D1 to D12 (one session per day from Monday to Friday, for two consecutive weeks, i.e. a total of ten sessions). Each tDCS session lasts 30 minutes at an intensity of 2 mA and is preceded by symptom provocation using a standardized procedure performed by trained personnel. The patients are then assessed on D42 and D102 (i.e. 1 month and 3 months after the end of the tDCS sessions).
CONDITIONS
Official Title
tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient suffering from OCD evolving for at least 2 years diagnosed according to DSM-V criteria
- Patient with good insight, defined by a score less than or equal to 18 on the Brown Assessment of Beliefs Scale
- Absence of a current depressive episode (MADRS score < 21) or suicidal risk (MADRS score item 10 < 3)
- Absence of epileptic pathology
- Chronic OCD defined by a total YBOCS score > 20, or a subscale score > 15
- Drug-resistant OCD despite treatment with at least 2 antidepressants of the IRS type at an effective dose and duration and/or behavioral and cognitive therapy for at least 1 year
- Therapeutic stability on antidepressants for more than 12 weeks without significant improvement
- Patient aged between 18 and 70 years
- Patient has given informed consent after receiving written information
- Patient has social security or equivalent coverage
You will not qualify if you...
- Woman of childbearing age without effective contraception
- Pregnant or nursing woman
- Patient hospitalized under duress
- Patient under guardianship or curatorship
- Patient with other DSM-V Axis 1 diagnoses such as Schizophrenic Disorder, Bipolar Disorder, Substance Abuse or Dependence
- Current depressive episode
- Patient at risk of suicide
- Patient with skin lesions on the scalp
- History of head trauma
- Patient with intracerebral metal object
- Patient with a pacemaker
- Presence of epileptic pathology
- Patient in an emergency situation or unable to give personal consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Henri Laborit
Poitiers, France
Actively Recruiting
Research Team
G
Ghina HARIKA-GERMANEAU, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here